Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Additional trials of Dermagraft to start:

This article was originally published in Clinica

Executive Summary

The FDA has given Advanced Tissue Sciences (ATS) permission to begin additional trials of its Dermagraft skin replacement product for treating diabetic foot ulcers. The US agency told ATS in June that it must start a new trial of the skin before it can be approved (see Clinica No 812, p14). The new trial will include up to 30 centres and will involve 330 patients over 18 months. However, if an interim study of 180 treatments shows results equivalent to the previous PMA trial, the new trial could be stopped after one year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT083165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel